https://www.selleckchem.com/pr....oducts/omaveloxolone
Patients with ≥ 1 CTM3-4/6 mL have shorter median progression-free survival and median overall survival. Unlike CTM2 and CTM3-4, which are detectable in pre-therapy and post-therapy, larger aggregated CTM≥5 (CTM with ≥ 5 CTCs) was only intra-therapeutically detected in four HER2+ GC patients, of which three experienced liver metastases. Obtained results suggested that the cluster size of GC-CTM should be dynamically profiled beyond pre-therapeutic whole CTM enumeration in terms of chemo-/targeted resistance or metastasis m
Like
Comment
Share
